Bridge Biotherapeutics Releases Preclinical Study Abstract of 4th Generation Lung Cancer Targeted Therapy BBT-207 at AACR

[Asia Economy Reporter Lee Gwan-joo] Innovative new drug research and development company Bridge Biotherapeutics announced on the 10th that the preclinical research abstract of 'BBT-207,' a 4th-generation targeted therapy candidate for lung cancer to be presented in poster form at next month's American Association for Cancer Research (AACR) Annual Meeting, has been released on the AACR website.

BBT-207, a new drug candidate discovered by Bridge Biotherapeutics, is a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) that targets the C797S-specific EGFR double mutation.

C797S is a resistance mutation that appears after treatment with 3rd-generation EGFR inhibitors such as Tagrisso (generic name Osimertinib), which are widely used in non-small cell lung cancer treatment. As Tagrisso expands its role as a first-line treatment, the need for new therapeutic options targeting various mutations, including C797S-positive double mutations, is increasing. BBT-207 is being developed as a treatment option targeting these double mutations, including C797S.

Bridge Biotherapeutics plans to attend the AACR offline event and reveal for the first time the preclinical research results related to the tumor suppression efficacy of BBT-207 in poster form. BBT-207 is accelerating development with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) within this year.

Jimmy Jin, Vice President of Bridge Biotherapeutics, said, “We are honored to disclose the key preclinical data of BBT-207, which targets the C797S double mutation, for the first time at a global academic conference,” adding, “In the increasingly diverse non-small cell lung cancer treatment market, we will do our best to achieve meaningful results in the future by quickly responding to market demands through BBT-207 alongside BBT-176.”

Bridge Biotherapeutics is developing BBT-176, a first-in-class clinical-stage candidate as a 4th-generation targeted therapy for C797S-positive triple mutations in lung cancer. Along with this, the company is continuing companion diagnostic research related to genetic mutations and is dedicated to developing innovative treatments in the field of non-small cell lung cancer.

This content was produced with the assistance of AI translation services.